265989-36-4

Usage

Uses

1. Pharmaceutical Industry:
Tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-(4-hydroxyphenylcarbamoyl)-5-isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate is used as an intermediate in the synthesis of Atorvastin, a selective, competitive HMG-CoA reductase inhibitor. This drug is specifically indicated for lowering elevated LDL-cholesterol and triglycerides in patients with hypercholesterolemia.
2. Research and Development:
In the field of research and development, tert-butyl 2-((4R,6R)-6-(2-(2-(4- fluorophenyl)-4-(4- hydroxyphenylcarbamoyl)-5-isopropyl-3- phenyl-1H-pyrrol-1-yl)ethyl)-2,2- dimethyl-1,3-dioxan-4-yl)acetate may be utilized for further exploration of its chemical properties, potential applications, and possible modifications to enhance its therapeutic effects or develop new drugs based on its structure.
Chemical Properties:
Tert-butyl 2-((4R,6R)-6-(2-(2-(4-fluorophenyl)-4-(4-hydroxyphenylcarbamoyl)-5-isopropyl-3-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate is a white solid, which indicates its stability and potential for use in various pharmaceutical formulations.

InChI:InChI=1/C40H47FN2O6/c1-25(2)36-35(38(46)42-29-17-19-30(44)20-18-29)34(26-11-9-8-10-12-26)37(27-13-15-28(41)16-14-27)43(36)22-21-31-23-32(48-40(6,7)47-31)24-33(45)49-39(3,4)5/h8-20,25,31-32,44H,21-24H2,1-7H3,(H,42,46)/t31-,32-/m1/s1

Upstream product

• 163217-68-3 tert-butyl 2-((4R,6R)-6-(2-(3-((4-(benzyloxy)phenyl)carbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 42558-54-3 Methyl 4-methyl-3-oxopentanoate 
• 6373-46-2 p-benzyloxyaniline 
• 265989-30-8 N-(4-(benzyloxy)phenyl)-4-methyl-3-oxopentanamide 
• 163217-67-2 N-(4-(benzyloxy)phenyl)-2-(2-(4-fluorophenyl)-2-oxo-1-phenylethyl)-4-methyl-3-oxopentanamide 

Downstream Products

• 918867-48-8 C₄₆H₅₇FN₂O₈ 
• 163217-70-7 p-Hydroxyatorvastatin lactone 
• 214217-88-6 p-Hydroxyatorvastatin 

Relevant academic research and scientific papers

Atorvastatin Derived HMG-CoA Reductase Degradation Inducing Compound

The present invention relates to a HMG-CoA reductase degradation-inducing compound and, more specifically, to a bifunctional compound in which atorvastatin and E3 ubiquitin ligase binding moiety are chemically linked as HMG-CoA reductase binding moiety, to a production method thereof, to a HMG-CoA reductase degradation method using the same, and to a pharmaceutical composition for preventing or treating HMG-CoA reductase-related diseases, comprising the same.

Synthesis of deuterium-labeled atorvastatin and its metabolites for use as internal standards in a LC/MS/MS method developed for quantitation of the drug and its metabolites in human serum

D5-labeled isotopomers of atorvastatin, atorvastatin lactone and its hydroxy metabolites were synthesized as internal standards for use in a LC/MS/MS method developed for the simultaneous quantitative determination of atorvastatin and its hydroxy metabolites in human serum. d5-Atorvastatin and d5-atorvastatin lactone were prepared from d5-aniline whereas their corresponding hydroxy metabolites were synthesized using d5-benzaldehyde.